SARS-CoV-2VIRCHILLDNCT06224062
Virus and Bronchial Epithelium in Children and the Elderly
A study testing SARS-CoV-2, Adenovirus (AdV) and Rhinovirus in people with SARS-CoV-2, run by University Hospital, Bordeaux at 1 site in France.
Trial summary
The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology that account for differences in the response and susceptibility to respiratory viruses. Read more about this study
- Who is it for?
- Ages Up to 17 years
- Conditions the study is for
- SARS-CoV-2
- What is being tested?
- SARS-CoV-2, Adenovirus (AdV) and Rhinovirus
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteFrance
- Study dates
- 28 Oct 2022to 28 Apr 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- For pediatric patients requiring research-specific bronchial brushing:
- Child under 18 years old,
- Requiring bronchoscopy as part of routine care
- Having informed and signed consent from the holders of parental authority
- For pediatric patients whose bronchial brushing will be carried out as part of their care and for those whose surgical waste will be collected for research:
- Child under 18 years old,
Show all 13Show fewer
- Requiring as part of routine care bronchoscopy and brushing or bronchial fibroscopy under general anesthesia or surgical resection/lobectomy
- Having expressed their non-opposition to their child's participation in research
- For adult patients:
- Man or woman
- Aged 18 or over
- Requiring as part of the care, thoracic surgery such as lobectomy, pneumonectomy or lung transplantation in the Thoracic Surgery Department of Haut Lévêque du Chu Hospital in Bordeaux or inclusion in the TUBE study, described below.
- having received an information note and not having objected to their participation in the research
Who cannot join
- No affiliation or non-beneficiary of a social security system
- During a period of relative exclusion compared to another protocol
- Patient born before 36 weeks of amenorrhea
- Patient with a documented history of pulmonary fibrosis, primary pulmonary hypertension, cystic fibrosis, pulmonary malformation or chronic viral infections (hepatitis, HIV).
- Patient with any dental, nasopharyngeal or bronchial infection with fever (> 38°C) requiring systemic antibiotics in the previous 4 weeks
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Bordeaux University Hospital
Bordeaux, 33076
Michael FAYON, MDPhD, michael.fayon@chu-bordeaux.fr
Matthieu THUMEREL, MD
About this study
Official title: Comparison of SARS-CoV-2, AdenoVIRus and Rhinovirus Infection of the Respiratory Epithelium in CHILdren vs. the eLDerly
The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology that account for differences in the response and susceptibility to respiratory viruses. Epidemiology and cell-based data show that respiratory virus infections differentially affect children, adults or the elderly populations.
The current worldwide pandemic of SARS-CoV-2 clearly highlighted this notion with a large part of the deaths occurring in the elderly population and very few deaths amongst children. This may be linked to a decreased transmission and/or viral load with SARS-CoV-2 in children compared to adults and elderly. Less in the public eye is the observation that other major respiratory virus targeting the bronchial epithelium (BE) such as rhinovirus (RV) and adenovirus (AdV) cause important clinical feature in children and have a much lower incidence in adults and the elderly populations, which is the opposite to the situation with SARS-CoV-2. Based on this remarkable discrepancy between respiratory viruses the investigators hypothesize that intrinsic age-controlled properties of the respiratory epithelium under resting physiological conditions determine virus susceptibility and virus propagation.
Read the detailed description
The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology able to explain differences in the response to respiratory viruses. Several epidemiological and cell-based data have demonstrated that respiratory virus infections differentially affect children, adults or the elderly populations. Perhaps, this difference has been put most notably into the spotlight by the current worldwide pandemic of SARS-CoV-2 with a large part of the deaths occurring in the elderly population whereas very few deaths amongst children have been recorded. According to some studies, this could be linked to a decreased transmission and/or viral load with SARS-CoV-2 in children compared to adults and elderly. What is less in the public eye is the observation that other major respiratory virus targeting the bronchial epithelium such as rhinovirus and adenovirus cause important clinical feature in children and have a much lower incidence in adults and the elderly populations, which is the opposite to the situation with SARS-CoV-2. Based on this remarkable discrepancy between respiratory viruses the investigators hypothesize that intrinsic age-controlled properties of the respiratory epithelium under resting physiological conditions determines virus susceptibility and virus propagation. Such hypothesis is supported by the literature and our own strong preliminary data. A highly complementing consortium composed of experts in lung physiology, pulmonary transcriptomic, respiratory viruses and ultrastructure analysis will address the question. The investigators will use three major respiratory pathogens (AdV, RV and SARS-CoV-2) to infect reconstituted fully functional respiratory epithelium obtained from children, adults and elderly and study parameters of virus infection and epithelial response. This project should highlight specific therapeutic targets against respiratory viruses with a high prevalence in children such as rhinovirus and adenoviruses to increase the therapeutic arsenal of clinician against those infections.
- Conditions
- SARS-CoV-2
- Being tested
- SARS-CoV-2, Adenovirus (AdV), Rhinovirus, No Intervention
- Keywords
- Adenovirus, SARS-COV-2, Rhinovirus, Children, Elderly
- Medical subject headings
- Adenoviridae Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SARS-CoV-2Biological
Circulating strains of SARS-CoV-2 (including variants of concern) were already collected, cultured and purified. The Wuhan reference strain will be used in the VIRCHILLD study to infect cells.
Adenovirus (AdV)Biological
Infection with C-type viruses (e.g. HAd-C5) using bronchial epithelium from adult donors
RhinovirusBiological
RV is a member of the picornaviridae family; small non-enveloped viruses with a single strand positive RNA genome protected by an icosahedral capsid. They are divided in more than 160 serotypes classed in subtype A, B and C. RV-A and RV-C infections will be used in the VIRCHILLD study
No InterventionBiological
no infection
| Study group | Role | What they receive |
|---|---|---|
| children | Experimental | reconstituted fully functional respiratory epithelium obtained from children (0 -18 years old) Receives: Biological: SARS-CoV-2; Biological: Adenovirus (AdV); Biological: Rhinovirus; Biological: No Intervention |
| adults | Experimental | reconstituted fully functional respiratory epithelium obtained from adults (18 to 60 years old) Receives: Biological: SARS-CoV-2; Biological: Adenovirus (AdV); Biological: Rhinovirus; Biological: No Intervention |
| elderly | Experimental | reconstituted fully functional respiratory epithelium obtained from adults (over 60 years old) Receives: Biological: SARS-CoV-2; Biological: Adenovirus (AdV); Biological: Rhinovirus; Biological: No Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
number of viral particles - Rhinovirus - Children -24
number of viral particles produced at the apical level after 24 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children
Measured: after 24 hours of infection
number of viral particles - Adenovirus - Children -24
number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children
Measured: after 24 hours of infection
number of viral particles - SARS-CoV-2 - Children-24
number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children
Measured: after 24 hours of infection
number of viral particles - Rhinovirus - Adults-24
number of viral particles produced at the apical level after 24 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults
Measured: after 24 hours of infection
number of viral particles - Adenovirus - Adults-24
number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults
Measured: after 24 hours of infection
number of viral particles - SARS-CoV-2 - Adults-24
number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults
Measured: after 24 hours of infection
number of viral particles - Rhinovirus - elderly-24
number of viral particles produced at the apical level after 24 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people
Measured: after 24 hours of infection
number of viral particles - Adenovirus - Elderly-24
number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people.
Measured: after 24 hours of infection
number of viral particles - SARS-CoV-2 - Elderly-24
number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people.
Measured: after 24 hours of infection
Secondary outcomes (36)
number of viral particles - Rhinovirus - Children-48
number of viral particles produced at the apical level after 48 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children
Measured: after 48 hours of infection
number of viral particles - Rhinovirus - Children-72
number of viral particles produced at the apical level after 72 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children
Measured: after 72 hours of infection
number of viral particles - Rhinovirus - Children-96
number of viral particles produced at the apical level after 96 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children
Measured: after 96 hours of infection
number of viral particles - Rhinovirus - Children-168
number of viral particles produced at the apical level after 168 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children
Measured: after 168 hours of infection
number of viral particles - Adenovirus - Children -48
number of viral particles produced at the apical level after 48 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children
Measured: after 48 hours of infection
number of viral particles - Adenovirus - Children -72
number of viral particles produced at the apical level after 72 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children
Measured: after 72 hours of infection
number of viral particles - Adenovirus - Children -96
number of viral particles produced at the apical level after 96 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children
Measured: after 96 hours of infection
number of viral particles - Adenovirus - Children -168
number of viral particles produced at the apical level after 168 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children
Measured: after 168 hours of infection
number of viral particles - SARS-CoV-2 - Children-48
number of viral particles produced at the apical level after 48 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children
Measured: after 48 hours of infection
number of viral particles - SARS-CoV-2 - Children-72
number of viral particles produced at the apical level after 72 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children
Measured: after 72 hours of infection
number of viral particles - SARS-CoV-2 - Children-96
number of viral particles produced at the apical level after 96 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children
Measured: after 96 hours of infection
number of viral particles - SARS-CoV-2 - Children-168
number of viral particles produced at the apical level after 168 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children
Measured: after 168 hours of infection
number of viral particles - Adenovirus - Adults-48
number of viral particles produced at the apical level after 48 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults
Measured: after 48 hours of infection
number of viral particles - Adenovirus - Adults-72
number of viral particles produced at the apical level after 72 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults
Measured: after 72 hours of infection
number of viral particles - Adenovirus - Adults-96
number of viral particles produced at the apical level after 96 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults
Measured: after 96 hours of infection
number of viral particles - Adenovirus - Adults-168
number of viral particles produced at the apical level after 168 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults
Measured: after 168 hours of infection
number of viral particles - Rhinovirus - Adults-48
number of viral particles produced at the apical level after 48 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults
Measured: after 48 hours of infection
number of viral particles - Rhinovirus - Adults-72
number of viral particles produced at the apical level after 72 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults
Measured: after 72 hours of infection
number of viral particles - Rhinovirus - Adults-96
number of viral particles produced at the apical level after 96 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults
Measured: after 96 hours of infection
number of viral particles - Rhinovirus - Adults-168
number of viral particles produced at the apical level after 168 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults
Measured: after 168 hours of infection
number of viral particles - SARS-CoV-2 - Adults-48
number of viral particles produced at the apical level after 48 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults
Measured: after 48 hours of infection
number of viral particles - SARS-CoV-2 - Adults-72
number of viral particles produced at the apical level after 72 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults
Measured: after 72 hours of infection
number of viral particles - SARS-CoV-2 - Adults-96
number of viral particles produced at the apical level after 96 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults
Measured: after 96 hours of infection
number of viral particles - SARS-CoV-2 - Adults-168
number of viral particles produced at the apical level after 168 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults
Measured: after 168 hours of infection
number of viral particles - Rhinovirus - elderly-48
number of viral particles produced at the apical level after 48 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people
Measured: after 48 hours of infection
number of viral particles - Rhinovirus - elderly-72
number of viral particles produced at the apical level after 72 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people
Measured: after 72 hours of infection
number of viral particles - Rhinovirus - elderly-96
number of viral particles produced at the apical level after 96 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people
Measured: after 96 hours of infection
number of viral particles - Rhinovirus - elderly-168
number of viral particles produced at the apical level after 168 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people
Measured: after 168 hours of infection
number of viral particles - Adenovirus - Elderly-48
number of viral particles produced at the apical level after 48 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people.
Measured: after 48 hours of infection
number of viral particles - Adenovirus - Elderly-72
number of viral particles produced at the apical level after 72 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people.
Measured: after 72 hours of infection
number of viral particles - Adenovirus - Elderly-96
number of viral particles produced at the apical level after 96 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people.
Measured: after 96 hours of infection
number of viral particles - Adenovirus - Elderly-168
number of viral particles produced at the apical level after 168hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people.
Measured: after 168 hours of infection
number of viral particles - SARS-CoV-2 - Elderly-48
number of viral particles produced at the apical level after 48 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people.
Measured: after 48 hours of infection
number of viral particles - SARS-CoV-2 - Elderly-72
number of viral particles produced at the apical level after 72 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people.
Measured: after 72 hours of infection
number of viral particles - SARS-CoV-2 - Elderly-96
number of viral particles produced at the apical level after 96 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people.
Measured: after 96 hours of infection
number of viral particles - SARS-CoV-2 - Elderly-168
number of viral particles produced at the apical level after 168 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people.
Measured: after 168 hours of infection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2024
- Study start28 Oct 2022
- Primary completion28 Apr 2025 (estimated)
- Study completion28 Apr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SARS-CoV-2Studies of the same condition, open and under way.
- More trials run by University Hospital, BordeauxThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Michael FAYON, MDPhD, Principal investigator, University Hospital, Bordeaux
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06224062
- Sponsor's protocol ID
- CHUBX 2021/43
- Acronym
- VIRCHILLD
- Status last verified
- Dec 2023
- First submitted
- 22 Dec 2023
- Last updated
- 25 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of SARS-CoV-2, AdenoVIRus and Rhinovirus Infection of the Respiratory Epithelium in CHILdren vs. the eLDerly
- ClinicalTrials.gov ID
- NCT06224062
- Acronym / sponsor ID
- VIRCHILLD / CHUBX 2021/43
- Conditions
- SARS-CoV-2
- Keywords
- Adenovirus, SARS-COV-2, Rhinovirus, Children, Elderly
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Study start
- 28 Oct 2022 (actual)
- Primary completion
- 28 Apr 2025 (estimated)
- Study completion
- 28 Apr 2025 (estimated)
- First posted
- 25 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology that account for differences in the response and susceptibility to respiratory viruses. Epidemiology and cell-based data show that respiratory virus infections differentially affect children, adults or the elderly populations.
The current worldwide pandemic of SARS-CoV-2 clearly highlighted this notion with a large part of the deaths occurring in the elderly population and very few deaths amongst children. This may be linked to a decreased transmission and/or viral load with SARS-CoV-2 in children compared to adults and elderly. Less in the public eye is the observation that other major respiratory virus targeting the bronchial epithelium (BE) such as rhinovirus (RV) and adenovirus (AdV) cause important clinical feature in children and have a much lower incidence in adults and the elderly populations, which is the opposite to the situation with SARS-CoV-2. Based on this remarkable discrepancy between respiratory viruses the investigators hypothesize that intrinsic age-controlled properties of the respiratory epithelium under resting physiological conditions determine virus susceptibility and virus propagation.
Detailed description
The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology able to explain differences in the response to respiratory viruses. Several epidemiological and cell-based data have demonstrated that respiratory virus infections differentially affect children, adults or the elderly populations. Perhaps, this difference has been put most notably into the spotlight by the current worldwide pandemic of SARS-CoV-2 with a large part of the deaths occurring in the elderly population whereas very few deaths amongst children have been recorded. According to some studies, this could be linked to a decreased transmission and/or viral load with SARS-CoV-2 in children compared to adults and elderly. What is less in the public eye is the observation that other major respiratory virus targeting the bronchial epithelium such as rhinovirus and adenovirus cause important clinical feature in children and have a much lower incidence in adults and the elderly populations, which is the opposite to the situation with SARS-CoV-2. Based on this remarkable discrepancy between respiratory viruses the investigators hypothesize that intrinsic age-controlled properties of the respiratory epithelium under resting physiological conditions determines virus susceptibility and virus propagation. Such hypothesis is supported by the literature and our own strong preliminary data. A highly complementing consortium composed of experts in lung physiology, pulmonary transcriptomic, respiratory viruses and ultrastructure analysis will address the question. The investigators will use three major respiratory pathogens (AdV, RV and SARS-CoV-2) to infect reconstituted fully functional respiratory epithelium obtained from children, adults and elderly and study parameters of virus infection and epithelial response. This project should highlight specific therapeutic targets against respiratory viruses with a high prevalence in children such as rhinovirus and adenoviruses to increase the therapeutic arsenal of clinician against those infections.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| children | Experimental | Biological: SARS-CoV-2, Biological: Adenovirus (AdV), Biological: Rhinovirus, Biological: No Interventionreconstituted fully functional respiratory epithelium obtained from children (0 -18 years old) |
| adults | Experimental | Biological: SARS-CoV-2, Biological: Adenovirus (AdV), Biological: Rhinovirus, Biological: No Interventionreconstituted fully functional respiratory epithelium obtained from adults (18 to 60 years old) |
| elderly | Experimental | Biological: SARS-CoV-2, Biological: Adenovirus (AdV), Biological: Rhinovirus, Biological: No Interventionreconstituted fully functional respiratory epithelium obtained from adults (over 60 years old) |
Who may qualify
- Ages
- Up to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (13 listed)
- Child under 18 years old,
- Requiring bronchoscopy as part of routine care
- Having informed and signed consent from the holders of parental authority
- For pediatric patients whose bronchial brushing will be carried out as part of their care and for those whose surgical waste will be collected for research:
- Child under 18 years old,
Key exclusion criteria (5 listed)
- No affiliation or non-beneficiary of a social security system
- During a period of relative exclusion compared to another protocol
- Patient born before 36 weeks of amenorrhea
- Patient with a documented history of pulmonary fibrosis, primary pulmonary hypertension, cystic fibrosis, pulmonary malformation or chronic viral infections (hepatitis, HIV).
- Patient with any dental, nasopharyngeal or bronchial infection with fever (> 38°C) requiring systemic antibiotics in the previous 4 weeks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SARS-CoV-2Circulating strains of SARS-CoV-2 (including variants of concern) were already collected, cultured and purified. The Wuhan reference strain will be used in the VIRCHILLD study to infect cells. | Biological | adults, children, elderly |
| Adenovirus (AdV)Infection with C-type viruses (e.g. HAd-C5) using bronchial epithelium from adult donors | Biological | adults, children, elderly |
| RhinovirusRV is a member of the picornaviridae family; small non-enveloped viruses with a single strand positive RNA genome protected by an icosahedral capsid. They are divided in more than 160 serotypes classed in subtype A, B and C. RV-A and RV-C infections will be used in the VIRCHILLD study | Biological | adults, children, elderly |
| No Interventionno infection | Biological | adults, children, elderly |
Primary outcome
number of viral particles - Rhinovirus - Children -24
Time frame: after 24 hours of infection
number of viral particles produced at the apical level after 24 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children
number of viral particles - Adenovirus - Children -24
Time frame: after 24 hours of infection
number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children
number of viral particles - SARS-CoV-2 - Children-24
Time frame: after 24 hours of infection
number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children
number of viral particles - Rhinovirus - Adults-24
Time frame: after 24 hours of infection
number of viral particles produced at the apical level after 24 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults
number of viral particles - Adenovirus - Adults-24
Time frame: after 24 hours of infection
number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults
number of viral particles - SARS-CoV-2 - Adults-24
Time frame: after 24 hours of infection
number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults
number of viral particles - Rhinovirus - elderly-24
Time frame: after 24 hours of infection
number of viral particles produced at the apical level after 24 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people
number of viral particles - Adenovirus - Elderly-24
Time frame: after 24 hours of infection
number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people.
number of viral particles - SARS-CoV-2 - Elderly-24
Time frame: after 24 hours of infection
number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people.
36 secondary outcomes
number of viral particles - Rhinovirus - Children-48
Time frame: after 48 hours of infection
number of viral particles - Rhinovirus - Children-72
Time frame: after 72 hours of infection
number of viral particles - Rhinovirus - Children-96
Time frame: after 96 hours of infection
number of viral particles - Rhinovirus - Children-168
Time frame: after 168 hours of infection
number of viral particles - Adenovirus - Children -48
Time frame: after 48 hours of infection
number of viral particles - Adenovirus - Children -72
Time frame: after 72 hours of infection
number of viral particles - Adenovirus - Children -96
Time frame: after 96 hours of infection
number of viral particles - Adenovirus - Children -168
Time frame: after 168 hours of infection
number of viral particles - SARS-CoV-2 - Children-48
Time frame: after 48 hours of infection
number of viral particles - SARS-CoV-2 - Children-72
Time frame: after 72 hours of infection
number of viral particles - SARS-CoV-2 - Children-96
Time frame: after 96 hours of infection
number of viral particles - SARS-CoV-2 - Children-168
Time frame: after 168 hours of infection
number of viral particles - Adenovirus - Adults-48
Time frame: after 48 hours of infection
number of viral particles - Adenovirus - Adults-72
Time frame: after 72 hours of infection
number of viral particles - Adenovirus - Adults-96
Time frame: after 96 hours of infection
number of viral particles - Adenovirus - Adults-168
Time frame: after 168 hours of infection
number of viral particles - Rhinovirus - Adults-48
Time frame: after 48 hours of infection
number of viral particles - Rhinovirus - Adults-72
Time frame: after 72 hours of infection
number of viral particles - Rhinovirus - Adults-96
Time frame: after 96 hours of infection
number of viral particles - Rhinovirus - Adults-168
Time frame: after 168 hours of infection
number of viral particles - SARS-CoV-2 - Adults-48
Time frame: after 48 hours of infection
number of viral particles - SARS-CoV-2 - Adults-72
Time frame: after 72 hours of infection
number of viral particles - SARS-CoV-2 - Adults-96
Time frame: after 96 hours of infection
number of viral particles - SARS-CoV-2 - Adults-168
Time frame: after 168 hours of infection
number of viral particles - Rhinovirus - elderly-48
Time frame: after 48 hours of infection
number of viral particles - Rhinovirus - elderly-72
Time frame: after 72 hours of infection
number of viral particles - Rhinovirus - elderly-96
Time frame: after 96 hours of infection
number of viral particles - Rhinovirus - elderly-168
Time frame: after 168 hours of infection
number of viral particles - Adenovirus - Elderly-48
Time frame: after 48 hours of infection
number of viral particles - Adenovirus - Elderly-72
Time frame: after 72 hours of infection
number of viral particles - Adenovirus - Elderly-96
Time frame: after 96 hours of infection
number of viral particles - Adenovirus - Elderly-168
Time frame: after 168 hours of infection
number of viral particles - SARS-CoV-2 - Elderly-48
Time frame: after 48 hours of infection
number of viral particles - SARS-CoV-2 - Elderly-72
Time frame: after 72 hours of infection
number of viral particles - SARS-CoV-2 - Elderly-96
Time frame: after 96 hours of infection
number of viral particles - SARS-CoV-2 - Elderly-168
Time frame: after 168 hours of infection
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2024.
- Individual participant dataSharing planned: No
Related trials for SARS-CoV-2
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael FAYON, MDPhD principal investigator
University Hospital, Bordeaux
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SARS-CoV-2, Adenovirus (AdV) and Rhinovirus in people with SARS-CoV-2, run by University Hospital, Bordeaux at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Thomas TRIAN, PhD (05 55 47 30 27 50, thomas.trian@u-bordeaux.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
number of viral particles - Rhinovirus - Children -24 (time frame: after 24 hours of infection). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2024.